Arthritis Clinical Trials

The present prospective, single-center, clinical trial is designed to evaluate the hemostatic efficacy of the hemostatic sealer Aquamantys 6.0™ in patients managed with total hip arthroplasty (THA). It is hypothesized that Aquamantys 6.0™ can improve hemostasis following total hip arthroplasty. Comparison of the functional and clinical results between THA patients having been exposed to Aquamantys 6.0™ versus a control group will be analyzed using several outcome measures including the Harris Hip Score, SF-12 version2 and the visual analog pain scale (VAS) through the previously IRB approved ORTHO MIDAS registry. The primary variable of interest is transfusion requirements. However, of secondary interest will be; 1) change in pre- and postoperative hemoglobin levels, 2) estimated intraoperative total blood loss, 3) adverse effects, 4) range of motion, 5) length of stay, 6) total cost of blood products/patient, 7) walking distance, and 8) the need for ambulatory assistance such as canes and walkers.